Ramesk K Ramanathan, MD

Research output

Research output per year 1995 2020

• 16766 Citations
• 55 Scopus h-Index
• 185 Article
• 15 Review article
• 10 Comment/debate
• 3 Letter
• 2 More
  • 2 Chapter

Research output per year

Research output per year

Search results

• 2020

  Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)

  Ramanathan, R. K., Von Hoff, D. D., Eskens, F., Blumenschein, G., Richards, D., Genvresse, I., Reschke, S., Granvil, C., Skubala, A., Peña, C. & Mross, K., Dec 2020, In: Targeted Oncology. 15, 6, p. 803 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
  • 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide
  • Mitogen-Activated Protein Kinase Kinases
  • Phosphatidylinositol 3-Kinases
  • Neoplasms

• Nomogram for Estimating Overall Survival in Patients with Metastatic Pancreatic Cancer

  Goldstein, D., Von Hoff, D. D., Chiorean, E. G., Reni, M., Tabernero, J., Ramanathan, R. K., Botteman, M., Aly, A., Margunato-Debay, S., Lu, B., Louis, C. U., McGovern, D. & Lee, C. K., Jul 1 2020, In: Pancreas. 49, 6, p. 744-750 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nomograms
  • Pancreatic Neoplasms
  • Survival
  • gemcitabine
  • 130-nm albumin-bound paclitaxel

• Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

  De Jesus-Acosta, A., Sugar, E. A., O’Dwyer, P. J., Ramanathan, R. K., Von Hoff, D. D., Rasheed, Z., Zheng, L., Begum, A., Anders, R., Maitra, A., McAllister, F., Rajeshkumar, N. V., Yabuuchi, S., de Wilde, R. F., Batukbhai, B., Sahin, I. & Laheru, D. A., Feb 18 2020, In: British journal of cancer. 122, 4, p. 498-505 8 p.

  Research output: Contribution to journal › Article › peer-review

  • HhAntag691
  • 130-nm albumin-bound paclitaxel
  • gemcitabine
  • Adenocarcinoma
  • Pancreatic Neoplasms
  17 Scopus citations

• Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

  Ramanathan, R. K., Von Hoff, D. D., Eskens, F., Blumenschein, G., Richards, D., Genvresse, I., Reschke, S., Granvil, C., Skubala, A., Peña, C. & Mross, K., Apr 1 2020, In: Targeted Oncology. 15, 2, p. 163-174 12 p.

  Research output: Contribution to journal › Article › peer-review

  • N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
  • 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide
  • Mitogen-Activated Protein Kinase Kinases
  • Phosphatidylinositol 3-Kinases
  • Maximum Tolerated Dose
  4 Scopus citations

• Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors

  Strickler, J. H., LoRusso, P., Salgia, R., Kang, Y. K., Yen, C. J., Lin, C. C., Ansell, P., Motwani, M., Wong, S., Yue, H., Wang, L., Reilly, E., Afar, D., Naumovski, L. & Ramanathan, R. K., May 1 2020, In: Molecular cancer therapeutics. 19, 5, p. 1210-1217 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • anti-c antibody
  • Neoplasms
  • Response Evaluation Criteria in Solid Tumors
  • Pharmacokinetics
  • Safety
  8 Scopus citations

• Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

  Mahalingam, D., Patel, M. R., Sachdev, J. C., Hart, L. L., Halama, N., Ramanathan, R. K., Sarantopoulos, J., Völkel, D., Youssef, A., de Jong, F. A. & Tsimberidou, A. M., Sep 1 2020, In: British Journal of Clinical Pharmacology. 86, 9, p. 1836-1848 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Macrophage Migration-Inhibitory Factors
  • Antibodies
  • Neoplasms
  • Appointments and Schedules
  • Maximum Tolerated Dose
  2 Scopus citations

• Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment among Patients with Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial

  Jameson, G. S., Borazanci, E., Babiker, H. M., Poplin, E., Niewiarowska, A. A., Gordon, M. S., Barrett, M. T., Rosenthal, A., Stoll-D'Astice, A., Crowley, J., Shemanski, L., Korn, R. L., Ansaldo, K., Lebron, L., Ramanathan, R. K. & Von Hoff, D. D., Jan 2020, In: JAMA Oncology. 6, 1, p. 125-132 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Albumin-Bound Paclitaxel
  • gemcitabine
  • Pancreatic Neoplasms
  • Cisplatin
  • Clinical Trials
  15 Scopus citations
• 2019

  A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

  Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Cubillo Gracian, A., Mangel, L., Elez Fernandez, E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Jan 22 2019, In: British journal of cancer. 120, 2, p. 183-189 7 p.

  Research output: Contribution to journal › Article › peer-review

  • veliparib
  • Colorectal Neoplasms
  • Placebos
  • Bevacizumab
  • Neutropenia
  12 Scopus citations

• A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer

  Ramanathan, R. K., Thomas, G. W., Khorana, A. A., Shah, S., Zhou, C., Wong, S., Cole, G., James, D. & Gabrail, N. Y., Apr 1 2019, In: Oncology (Switzerland). 96, 4, p. 217-222 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Factor VIIa
  • gemcitabine
  • Pancreatic Neoplasms
  • Progression-Free Survival
  • Survival
  6 Scopus citations

• Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z)

  Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Gracian, A. C., Mangel, L., Fernandez, E. E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Aug 27 2019, In: British journal of cancer. 121, 5, p. 429-430 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • veliparib
  • Colorectal Neoplasms
  • Placebos
  • Neoplasms

• Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

  Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., Ahn, D. H., Bekaii-Saab, T. S. & Borad, M. J., Jun 2019, In: JAMA Oncology. 5, 6, p. 824-830 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Albumin-Bound Paclitaxel
  • Biliary Tract Neoplasms
  • gemcitabine
  • Nanoparticles
  • Cisplatin
  59 Scopus citations

• Hepatocytes direct the formation of a pro-metastatic niche in the liver

  Lee, J. W., Stone, M. L., Porrett, P. M., Thomas, S. K., Komar, C. A., Li, J. H., Delman, D., Graham, K., Gladney, W. L., Hua, X., Black, T. A., Chien, A. L., Majmundar, K. S., Thompson, J. C., Yee, S. S., O’Hara, M. H., Aggarwal, C., Xin, D., Shaked, A., Gao, M. & 9 others, Liu, D., Borad, M. J., Ramanathan, R. K., Carpenter, E. L., Ji, A., de Beer, M. C., de Beer, F. C., Webb, N. R. & Beatty, G. L., Mar 14 2019, In: Nature. 567, 7747, p. 249-252 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Hepatocytes
  • Liver
  • STAT3 Transcription Factor
  • Circulating Neoplastic Cells
  • Neoplasm Metastasis
  74 Scopus citations

• Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313

  Ramanathan, R. K., McDonough, S. L., Philip, P. A., Hingorani, S. R., Lacy, J., Kortmansky, J. S., Thumar, J., Chiorean, E. G., Shields, A. F., Behl, D., Mehan, P. T., Gaur, R., Seery, T., Guthrie, K. A. & Hochster, H. S., 2019, In: Journal of Clinical Oncology. 37, 13, p. 1062-1069 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Hyaluronoglucosaminidase
  • Adenocarcinoma
  • Hyaluronic Acid
  • Survival
  • Pancreatic Neoplasms
  55 Scopus citations
• 2018

  A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

  Berlin, J., Ramanathan, R. K., Strickler, J. H., Subramaniam, D. S., Marshall, J., Kang, Y. K., Hetman, R., Dudley, M. W., Zeng, J., Nickner, C., Xiong, H., Komarnitsky, P., Shepherd, S. P., Hurwitz, H. & Lenz, H. J., Apr 1 2018, In: British journal of cancer. 118, 7, p. 938-946 9 p.

  Research output: Contribution to journal › Article › peer-review

  • veliparib
  • Irinotecan
  • Fluorouracil
  • Leucovorin
  • Maximum Tolerated Dose
  7 Scopus citations

• A phase II clinical investigation of BPM31510-IV (ubidecarenone) in patients with advanced pancreatic cancer

  Niewiarowska, A. A., Lucius, D. M., Sarangarajan, R., Narain, N. R., Ramanathan, R., Ritch, P., Strauss, J., Kundranda, M. & Propper, D., Oct 1 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii270

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

  Moschos, S. J., Sullivan, R. J., Hwu, W. J., Ramanathan, R. K., Adjei, A. A., Fong, P. C., Shapira-Frommer, R., Tawbi, H. A., Rubino, J., Rush, T. S., Zhang, D., Miselis, N. R., Samatar, A. A., Chun, P., Rubin, E. H., Schiller, J., Long, B. J., Dayananth, P., Carr, D., Kirschmeier, P. & 8 others, Bishop, W. R., Deng, Y., Cooper, A., Shipps, G. W., Moreno, B. H., Robert, L., Ribas, A. & Flaherty, K. T., Feb 22 2018, In: JCI Insight. 3, 4

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • SCH772984
  • Melanoma
  • Neoplasms
  • Clinical Trials, Phase I
  • Exanthema
  41 Scopus citations

• Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma

  Ahn, D. H., Ramanathan, R. K. & Bekaii-Saab, T., Jun 11 2018, In: Cancers. 10, 6, 193.

  Research output: Contribution to journal › Review article › peer-review

  • Immune System
  • Adenocarcinoma
  • Direction compound
  • Neoplasms
  • Tumor Microenvironment
  6 Scopus citations

• Erratum: Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours (British journal of cancer (2018) 118 2 (153-161))

  Infante, J. R., Korn, R. L., Rosen, L. S., LoRusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., Von Hoff, D. D., Borad, M. J. & Ramanathan, R. K., Jan 1 2018, In: British journal of cancer. 118, 2, p. e3

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Hyaluronoglucosaminidase
  • Neoplasms

• First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody–drug conjugate targeting c-Met, in patients with advanced solid tumors

  Strickler, J. H., Weekes, C. D., Nemunaitis, J., Ramanathan, R. K., Heist, R. S., Morgensztern, D., Angevin, E., Bauer, T. M., Yue, H., Motwani, M., Parikh, A., Reilly, E. B., Afar, D., Naumovski, L. & Kelly, K., Nov 20 2018, In: Journal of Clinical Oncology. 36, 33, p. 3298-3306 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-Small Cell Lung Carcinoma
  • Neoplasms
  • ABBV-399
  • Maximum Tolerated Dose
  • monomethyl auristatin E
  28 Scopus citations

• Metastatic pancreatic cancer: ASCO clinical practice guideline update

  Sohal, D. P. S., Kennedy, E. B., Khorana, A., Copur, M. S., Crane, C. H., Garrido-Laguna, I., Krishnamurthi, S., Moravek, C., O'Reilly, E. M., Philip, P. A., Ramanathan, R. K., Ruggiero, J. T., Shah, M. A., Urba, S., Uronis, H. E., Lau, M. W. & Laheru, D., Aug 20 2018, In: Journal of Clinical Oncology. 36, 24, p. 2545-2556 12 p.

  Research output: Contribution to journal › Review article › peer-review

  • Pancreatic Neoplasms
  • Practice Guidelines
  • Fluorouracil
  • Irinotecan
  • gemcitabine
  72 Scopus citations

• Novel immunotherapy strategies for hepatobiliary cancers

  Deleon, T. T., Zhou, Y., Nagalo, B. M., Yokoda, R. T., Ahn, D. H., Ramanathan, R. K., Salomao, M. A., Aqel, B. A., Mahipal, A., Bekaii-Saab, T. S. & Borad, M. J., Sep 1 2018, In: Immunotherapy. 10, 12, p. 1077-1091 15 p.

  Research output: Contribution to journal › Review article › peer-review

  • Immunotherapy
  • Neoplasms
  • Oncolytic Virotherapy
  • Chimeric Antigen Receptors
  • T-Lymphocytes

• Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma

  Deleon, T. T., Ahn, D., Bogenberger, J. M., Anastasiadis, P. Z., Arora, M., Ramanathan, R. K., Aqel, B. A., Vasmatzis, G., Truty, M., Oklu, R., Bekaii-Saab, T. & Borad, M. J., Mar 1 2018, In: Future Oncology. 14, 6, p. 553-566 14 p.

  Research output: Contribution to journal › Review article › peer-review

  • Biliary Tract Neoplasms
  • Hepatocellular Carcinoma
  • Nivolumab
  • Biomarkers
  • Neoplasms
  13 Scopus citations

• Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

  Infante, J. R., Korn, R. L., Rosen, L. S., Lorusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., Von Hoff, D. D., Borad, M. J. & Ramanathan, R. K., Jan 1 2018, In: British journal of cancer. 118, 2, p. 153-161 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Hyaluronoglucosaminidase
  • Neoplasms
  • Hyaluronic Acid
  • Maximum Tolerated Dose
  • Myalgia
  33 Scopus citations

• Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

  Weiss, G. J., Jameson, G., Von Hoff, D. D., Valsasina, B., Davite, C., Di Giulio, C., Fiorentini, F., Alzani, R., Carpinelli, P., Di Sanzo, A., Galvani, A., Isacchi, A. & Ramanathan, R. K., Feb 1 2018, In: Investigational New Drugs. 36, 1, p. 85-95 11 p.

  Research output: Contribution to journal › Article › peer-review

  • polo-like kinase 1
  • Maximum Tolerated Dose
  • Oral Administration
  • Neoplasms
  • Safety
  12 Scopus citations

• Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma

  Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., El-Khoueiry, A., Kelley, R. K., Borbath, I., Choo, S. P., Oh, D. Y., Philip, P. A., Chen, L. T., Reungwetwattana, T., Van Cutsem, E., Yeh, K. H. & 9 others, Ciombor, K., Finn, R. S., Patel, A., Sen, S., Porter, D., Isaacs, R., Zhu, A. X., Abou-Alfa, G. K. & Bekaii-Saab, T., Jan 20 2018, In: Journal of Clinical Oncology. 36, 3, p. 276-282 7 p.

  Research output: Contribution to journal › Article › peer-review

  • 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
  • Receptor, Fibroblast Growth Factor, Type 2
  • Cholangiocarcinoma
  • Hyperphosphatemia
  • Stomatitis
  193 Scopus citations

• Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors

  Lam, E. T., Eckhardt, S. G., Messersmith, W., Jimeno, A., O'Bryant, C. L., Ramanathan, R. K., Weiss, G. J., Chadha, M., Oey, A., Ding, H. T., Culp, P. A., Keller, S. F., Zhao, V. Y., Tsao, L. C., Singhal, A., Holen, K. D. & Von Hoff, D., Jan 2018, In: Molecular cancer therapeutics. 17, 1, p. 215-221 7 p.

  Research output: Contribution to journal › Article › peer-review

  • enavatuzumab
  • TWEAK Receptor
  • Antibodies, Monoclonal, Humanized
  • Pharmacokinetics
  • Neoplasms
  7 Scopus citations
• 2017

  ¹⁸F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

  Korn, R. L., Von Hoff, D. D., Borad, M. J., Renschler, M. F., McGovern, D., Curtis Bay, R. & Ramanathan, R. K., Aug 3 2017, In: Cancer Imaging. 17, 1, 23.

  Research output: Contribution to journal › Article › peer-review

  • 130-nm albumin-bound paclitaxel
  • gemcitabine
  • Positron Emission Tomography Computed Tomography
  • Fluorodeoxyglucose F18
  • Pancreatic Neoplasms
  4 Scopus citations

• A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients

  Ramanathan, R. K., Weiss, G. J., Posner, R. G., Rajeshkumar, N. V., Jameson, G., Aziz, M., Hoering, A., Bolejack, V., Maitra, A., Fulk, M., Stites, E. C., Hlavacek, W. S., Gatalica, Z., Xiu, J., Hidalgo, M., Von Hoff, D. D. & Barrett, M. T., Dec 1 2017, In: Journal of Gastrointestinal Oncology. 8, 6, p. 925-935 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Pancreatic Neoplasms
  • Immunohistochemistry
  • Neoplasms
  • Biopsy
  • Therapeutics

• Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

  Barrett, M. T., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., Velculescu, V. E., Drebin, J., O'Dwyer, P., Jameson, G., Ramanathan, R. K. & Von Hoff, D. D., Aug 8 2017, In: British journal of cancer. 117, 4, p. 572-582 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Adenocarcinoma
  • Clinical Studies
  • Genome
  • DNA Repair-Deficiency Disorders
  • Clinical Trials
  15 Scopus citations

• Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: A pilot study

  Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., Cain, J., Hendriks, B. S., Drummond, D. C., Bayever, E. & Fitzgerald, J. B., Jul 15 2017, In: Clinical Cancer Research. 23, 14, p. 3638-3648 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Ferrosoferric Oxide
  • Irinotecan
  • Neoplasms
  • Permeability
  • Iron
  78 Scopus citations

• Development of new pharmaceutical therapies for pancreatic adenocarcinoma

  Ramanathan, R. K., Nov 2017, In: Clinical Advances in Hematology and Oncology. 15, 11, p. 7-10 4 p.

  Research output: Contribution to journal › Article › peer-review

• Immunotherapy in pancreatic cancer treatment: A new frontier

  Thind, K., Padrnos, L. J., Ramanathan, R. K. & Borad, M. J., Jan 1 2017, In: Therapeutic Advances in Gastroenterology. 10, 1, p. 168-194 27 p.

  Research output: Contribution to journal › Review article › peer-review

  • Pancreatic Neoplasms
  • Immunotherapy
  • Tumor Microenvironment
  • Immune Tolerance
  • Standard of Care
  41 Scopus citations

• Molecular modeling and functional analysis of exome sequencing-derived variants of unknown significance identify a novel, constitutively active FGFR2 mutant in cholangiocarcinoma

  Egan, J. B., Marks, D. L., Hogenson, T. L., Vrabel, A. M., Sigafoos, A. N., Tolosa, E. J., Carr, R. M., Safgren, S. L., Hesles, E. E., Almada, L. L., Romecin-Duran, P. A., Iguchi, E., Ala'Aldeen, A., Kocher, J. P. A., Oliver, G. R., Prodduturi, N., Mead, D. W., Hossain, A., Huneke, N. E., Tagtow, C. M. & 43 others, Ailawadhi, S., Ansell, S. M., Banck, M. S., Bryce, A. H., Carballido, E. M., Chanan-Khan, A. A., Curtis, K. K., Resnik, E., Gawryletz, C. D., Go, R. S., Halfdanarson, T. R., Ho, T. H., Joseph, R. W., Kapoor, P., Mansfield, A. S., Meurice, N., Rao, A. A. N., Nowakowski, G. S., Pardanani, A., Parikh, S. A., Cheville, J. C., Feldman, A. L., Ramanathan, R. K., Robinson, S. I., Tibes, R., Finnes, H. D., McCormick, J. B., McWilliams, R. R., Jatoi, A., Patnaik, M. M., Silva, A. C., Wieben, E. D., McAllister, T. M., Rumilla, K. M., Kerr, S. E., Lazaridis, K. N., Farrugia, G., Keith Stewart, A., Clark, K. J., Kennedy, E. J., Klee, E. W., Borad, M. J. & Fernandez-Zapico, M. E., 2017, In: JCO Precision Oncology. 2017, 1, p. 1-13 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Exome
  • Cholangiocarcinoma
  • Computer Simulation
  • Genes
  • Mutation
  1 Scopus citations

• Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers

  de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., Henshaw, J. W., Herriott, A., Patterson, M., Curtin, N. J., Byers, L. A. & Wainberg, Z. A., 2017, In: Cancer discovery. 7, 6, p. 620-629 10 p.

  Research output: Contribution to journal › Article › peer-review

  • talazoparib
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Mutation
  • Neoplasms
  • Small Cell Lung Carcinoma
  178 Scopus citations

• Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors

  Juric, D., Krop, I., Ramanathan, R. K., Wilson, T. R., Ware, J. A., Sanabria Bohorquez, S. M., Savage, H. M., Sampath, D., Salphati, L., Lin, R. S., Jin, H., Parmar, H., Hsu, J. Y., Von Hoff, D. D. & Baselga, J., Jul 2017, In: Cancer discovery. 7, 7, p. 704-715 12 p.

  Research output: Contribution to journal › Article › peer-review

  • 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide
  • Phosphatidylinositol 3-Kinases
  • Neoplasms
  • Breast Cancer 3
  • Growth Inhibitors
  75 Scopus citations

• Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis

  Borazanci, E., Millis, S. Z., Kimbrough, J., Doll, N., von Hoff, D. & Ramanathan, R. K., 2017, In: Journal of Gastrointestinal Oncology. 8, 1, p. 164-172 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Appendiceal Neoplasms
  • Fluorescence In Situ Hybridization
  • Immunohistochemistry
  • multidrug resistance-associated protein 1
  • Goblet Cells
  24 Scopus citations

• Recent advances in the treatment of pancreatic adenocarcinoma: Further observations

  Ramanathan, R. K. & Bekaii-Saab, T., Nov 1 2017, In: Clinical Advances in Hematology and Oncology. 15, 11, 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Recent advances in the treatment of pancreatic adenocarcinoma

  Braiteh, F., Ramanathan, R. K. & Bekaii-Saab, T., Nov 1 2017, In: Clinical Advances in Hematology and Oncology. 15, 11, p. 1-2 2 p.

  Research output: Contribution to journal › Article › peer-review

  • Pancreatic Neoplasms
  • Adenocarcinoma
  • gemcitabine
  • Leucovorin
  • Irinotecan

• Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer

  Goldstein, D., Von Hoff, D., Chiorean, E., Reni, M., Tabernero, J., Ramanathan, R., Wilkerson, J., Botteman, M., Aly, A., Margunato-Debay, S., Lu, B., Louis, C., Renschler, M., McGovern, D. & Lee, C., Jun 1 2017, In: Annals of oncology : official journal of the European Society for Medical Oncology. 28, p. iii142-iii144

  Research output: Contribution to journal › Article › peer-review

  Open Access
  12 Scopus citations

• Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis

  Sonbol, M. B., Firwana, B., Wang, Z., Almader-Douglas, D., Borad, M. J., Makhoul, I., Ramanathan, R. K., Ahn, D. & Bekaii-Saab, T., Dec 1 2017, In: Cancer. 123, 23, p. 4680-4686 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Adenocarcinoma
  • Progression-Free Survival
  • Meta-Analysis
  • Oxaliplatin
  • Irinotecan
  17 Scopus citations

• Targeting the stroma in pancreatic cancer

  Ahn, D. & Ramanathan, R. K., Dec 1 2017, In: Chinese Clinical Oncology. 6, 6, 65.

  Research output: Contribution to journal › Review article › peer-review

  • Pancreatic Neoplasms
  • Tumor Microenvironment
  • Immunosuppression
  • Therapeutic Uses
  • Adenocarcinoma
  3 Scopus citations

• Tumor reduction in primary andmetastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine: An exploratory analysis from a phase 3 study

  Kunzmann, V., Ramanathan, R. K., Goldstein, D., Liu, H., Ferrara, S., Lu, B., Renschler, M. F. & Von Hoff, D. D., 2017, In: Pancreas. 46, 2, p. 203-208 6 p.

  Research output: Contribution to journal › Article › peer-review

  • 130-nm albumin-bound paclitaxel
  • gemcitabine
  • Pancreatic Neoplasms
  • Tumor Burden
  • Adenocarcinoma
  16 Scopus citations

• Virotherapies in pancreatic cancer

  Ahn, D. & Ramanathan, R. K., Sep 27 2017, Current and Emerging Therapies in Pancreatic Cancer. Springer International Publishing, p. 309-322 14 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter
• 2016

  A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab

  Christiansen, M. E., Ingall, T., Lew, E. C., Ramanathan, R. K. & Paripati, H. R., 2016, In: Case Reports in Oncology. 9, 2, p. 317-320 4 p.

  Research output: Contribution to journal › Article › peer-review

  • ramucirumab
  • Vascular Endothelial Growth Factor Receptor-2
  • Stomach Neoplasms
  • Stroke
  • Thromboembolism
  1 Scopus citations

• CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

  Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B. & Ko, A., Apr 1 2016, In: Annals of Oncology. 27, 4, p. 654-660 7 p., mdw006.

  Research output: Contribution to journal › Article › peer-review

  • 130-nm albumin-bound paclitaxel
  • gemcitabine
  • Pancreatic Neoplasms
  • Survival
  • 3-(3'-diethylaminopropyl-(1')-carbamoyl)-6,7-dimethoxy-1-thiaisochroman-1,1-dioxide
  54 Scopus citations

• Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A cohort study

  Kasi, P. M., Kotani, D., Cecchini, M., Shitara, K., Ohtsu, A., Ramanathan, R. K., Hochster, H. S., Grothey, A. & Yoshino, T., Jul 13 2016, In: BMC cancer. 16, 1, 467.

  Research output: Contribution to journal › Article › peer-review

  • trifluridine tipiracil
  • Neutropenia
  • Colorectal Neoplasms
  • Cohort Studies
  • Drug Therapy
  38 Scopus citations

• Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers

  Borad, M. J., Egan, J. B., Condjella, R. M., Liang, W. S., Fonseca, R., Ritacca, N. R., McCullough, A. E., Barrett, M. T., Hunt, K. S., Champion, M. D., Patel, M. D., Young, S. W., Silva, A. C., Ho, T. H., Halfdanarson, T. R., McWilliams, R. R., Lazaridis, K. N., Ramanathan, R. K., Baker, A., Aldrich, J. & 17 others, Kurdoglu, A., Izatt, T., Christoforides, A., Cherni, I., Nasser, S., Reiman, R., Cuyugan, L., McDonald, J., Adkins, J., Mastrian, S. D., Valdez, R., Jaroszewski, D. E., Von Hoff, D. D., Craig, D. W., Stewart, A. K., Carpten, J. D. & Bryce, A. H., 2016, In: Scientific reports. 6, 1, 25.

  Research output: Contribution to journal › Article › peer-review

  • Neoplasms
  • DNA Fingerprinting
  • Therapeutics
  • Patient Preference
  • Pharmaceutical Preparations
  11 Scopus citations

• Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)

  Goldstein, D., Von Hoff, D. D., Moore, M., Greeno, E., Tortora, G., Ramanathan, R. K., Macarulla, T., Liu, H., Pilot, R., Ferrara, S. & Lu, B., Jan 2016, In: European Journal of Cancer. 52, p. 85-91 7 p.

  Research output: Contribution to journal › Article › peer-review

  • 130-nm albumin-bound paclitaxel
  • gemcitabine
  • Peripheral Nervous System Diseases
  • Pancreas
  • Adenocarcinoma
  20 Scopus citations

• Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: Phase III MPACT trial

  Scheithauer, W., Ramanathan, R. K., Moore, M., Macarulla, T., Goldstein, D., Hammel, P., Kunzmann, V., Liu, H., McGovern, D., Romano, A. & Von Hoff, D. D., Jun 1 2016, In: Journal of Gastrointestinal Oncology. 7, 3, p. 469-478 10 p.

  Research output: Contribution to journal › Article › peer-review

  • 130-nm albumin-bound paclitaxel
  • gemcitabine
  • Pancreatic Neoplasms
  • Neutropenia
  • Thrombocytopenia
  27 Scopus citations

• First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

  Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J. M., Lotze, M. T., Toledo, F. G. S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I. & 1 others, Ramanathan, R. K., 2016, In: Annals of Oncology. 27, 10, p. 1928-1940 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide
  • Class I Phosphatidylinositol 3-Kinases
  • Non-Hodgkin's Lymphoma
  • Maximum Tolerated Dose
  • Neoplasms
  104 Scopus citations